# EDGAR Filing Document

**Accession Number:** 0001022079
**File Stem:** 0000947871-26-000244
**Filing Date:** 2026-3
**Character Count:** 9300
**Document Hash:** b0a29640661a818738d1ab434e53f668
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000947871-26-000244.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0000947871-26-000244

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260309

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QUEST DIAGNOSTICS INC
- **CENTRAL INDEX KEY:** 0001022079
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 161387862
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12215
- **FILM NUMBER:** 26748311

**BUSINESS ADDRESS:**
- **STREET 1:** 500 PLAZA DRIVE
- **CITY:** SECAUCUS
- **STATE:** NJ
- **ZIP:** 07094
- **BUSINESS PHONE:** 9735202700

**MAIL ADDRESS:**
- **STREET 1:** 500 PLAZA DRIVE
- **CITY:** SECAUCUS
- **STATE:** NJ
- **ZIP:** 07094

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CORNING CLINICAL LABORATORIES INC
- **DATE OF NAME CHANGE:** 19960903

?xml version='1.0' encoding='ASCII'?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report** (Date of Earliest Event Reported)**: March 9, 2026**

**Quest Diagnostics Incorporated**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other jurisdiction of incorporation)

---

| | | |
|:---|:---|:---|
| **001-12215** |  | **16-1387862** |
| (Commission File Number) |  | (I.R.S. Employer Identification No.) |
| **500 Plaza Drive** |  |  |
| **Secaucus, NJ** |  | **07094** |
| (Address of principal executive offices) |  | (Zip Code) |
|  | **(973) 520-2700** |  |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.01 Par Value | DGX | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) On March 9, 2026, the Board of Directors (the "Board") of Quest Diagnostics Incorporated (the "Company"), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. The Board appointed Mr. Wentworth to serve on the Board's Compensation and Leadership Development Committee and the Board's Quality and Compliance Committee.

The Board determined that Mr. Wentworth is an independent director pursuant to the New York Stock Exchange listing standards and the Company's independence guidelines, as set forth in its corporate governance guidelines.

Mr. Wentworth will receive compensation as a non-employee director in accordance with the Company's non-employee director compensation practices. As part of that compensation, Mr. Wentworth received a prorated one-time grant of restricted share units valued at approximately $43,000 upon becoming a member of the Company's Board.

**Item 7.01. Regulation FD Disclosure.**

A copy of the Company's press release announcing the election of Mr. Wentworth as a director of the Board is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits.

99.1 [Press release dated March 12, 2026.](ss6056588_ex9901.htm) <br>104 The cover page from this current report on Form 8-K, formatted in Inline XBRL.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 12, 2026

---

| | |
|:---|:---|
| QUEST DIAGNOSTICS INCORPORATED | QUEST DIAGNOSTICS INCORPORATED |
| By: | /s/ Sean D. Mersten |
|  | Vice President and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors**

**SECAUCUS, N.J., March 12, 2026** -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director. Including Mr. Wentworth, the company's board has eleven members.

"As a former CEO of several large, publicly traded healthcare organizations, Tim brings incredible leadership experience to the Quest board," said Jim Davis, chairman, CEO and president of Quest Diagnostics. "His depth in the many channels Quest serves, including health plan, employer and consumer, combined with his real-world operations and HR expertise, makes him an exceptional addition to the Quest team as we work together to create a healthier world, one life at a time."

Mr. Wentworth, 65, was most recently chief executive officer (CEO) of Walgreens Boots Alliance, where he helped restructure the company for its sale to Sycamore Partners in mid-2025. Prior to that, he was founding CEO of Evernorth Health Services, the health services organization of The Cigna Group that partners with health plans, employers and government organizations to deliver pharmacy, care, and benefit solutions.

In addition, Mr. Wentworth was president and CEO of Express Scripts, one of the largest pharmacy benefit managers in the United States, following the company's 2012 acquisition of Medco Health Solutions, where he held roles as group president, employer accounts and president and CEO of Medco's Accredo Health specialty pharmacy business. With the Medco transaction, Express Scripts grew into a Fortune 25 company with more than $100 billion in revenues before its acquisition by Cigna in 2018.

Mr. Wentworth's experience also includes senior leadership roles with top consumer brands, including chief operating officer at Mary Kay, Inc., and director roles in human resources at PepsiCo, Inc.

Timothy M. Ring, lead independent director, added: "Tim is an accomplished business leader who knows how to run highly complex, industry-leading healthcare companies to generate growth and value at scale. We are fortunate to welcome him to our board."

Mr. Wentworth serves on the boards of directors of Walgreens Holding Company and dfinitiv, and previously served on the boards of Walgreens Boots Alliance, Accredo Health Group, Express Scripts, and Forge Health. He earned his bachelor's degree in industrial and labor relations from Cornell University and an associate in applied science degree in business administration from Monroe Community College.

**About Quest Diagnostics**

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. <u>www.QuestDiagnostics.com</u>

SOURCE Quest Diagnostics

For further information: Dan Haemmerle (Investors): 973-520-2900 or Wendy Bost (Media): 973-520-2800